| Officer | Age | In this role | Joined | Source |
|---|---|---|---|---|
|
Stéphane Bancel
Also a director
Chief Executive Officer
|
53 |
Since 2011
15 years
|
2011 | |
|
Stephane Bancel
Chief Executive Officer
Title from the Form 4 dated Aug 5, 2026
|
Not stated | Not stated | Not stated | |
|
James Mock
Chief Financial Officer
|
49 |
Since 2022
4 years
|
2022 | |
|
Stephen Hoge
President
|
50 |
Since 2024
2 years
|
2013 | |
|
Juan Andres
Chief Operating Officer
Title from the Form 4 dated Nov 5, 2026
|
Not stated | Not stated | Not stated | |
|
David Berman
Chief Development Officer
|
55 |
Since 2026
this year
|
2026 | |
|
Tracey Franklin
Chief People and Digital Technology Officer
|
46 |
Since 2024
2 years
|
2019 | |
|
Shannon Thyme Klinger
Chief Legal Officer and Corporate Secretary
|
54 |
Since 2021
5 years
|
2021 | |
|
Soria Ester Banque
Chief Commercial Officer
Title from the Form 4 dated Jul 5, 2026
|
Not stated | Not stated | Not stated | |
|
Rose Loughlin
Executive Vice President, Research
|
42 |
Since 2024
2 years
|
2016 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Mar 16, 2026 · updated by the 8-K of Jul 8, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Noubar Afeyan
Board chair
|
63 |
2010
16 years
|
Independent | None stated | Generate Biomedicines, Inc. | Not stated | |
|
Stéphane Bancel
CEO
|
53 |
2011
15 years
|
Not independent | None stated | Generate Biomedicines, Inc. | Paid as CEO | |
|
Sandra Horning
|
77 |
2020
6 years
|
Independent |
Product and Technology · Chair
Nominating and Corporate Governance
|
Revolution Medicines, Inc. | $563,290 | |
|
Abbas Hussain
|
61 |
2024
2 years
|
Independent |
Audit
Product and Technology
|
None stated | $543,290 | |
|
Elizabeth Nabel
|
74 |
2015
11 years
|
Independent |
Compensation and Talent
Product and Technology
|
Medtronic plc | $543,290 | |
|
François Nader
|
69 |
2019
7 years
|
Independent |
Compensation and Talent · Chair
Nominating and Corporate Governance · Chair
|
Tectonic Therapeutic, Inc. | $583,267 | |
|
David Rubenstein
|
76 |
2024
2 years
|
Independent |
Nominating and Corporate Governance Committee
|
The Carlyle Group | $543,272 | |
|
Elizabeth Tallett
|
76 |
2020
6 years
|
Independent |
Audit · Chair
Compensation and Talent
|
Qiagen, Inc. | $563,277 | |
|
Sagan
|
Not stated | Not stated | Independent | None stated | None stated | Not stated | |
|
Michael McDonnell
Joined Jul 8, 2026
|
- | - | - |
Audit Committee
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Mar 16, 2026 states there were none.
Read it in the proxyLoading...